Left Upper Quadrant Discomfort After Greasy Meals: Functional Dyspepsia
This presentation is most consistent with functional dyspepsia (FD), and you should initiate a "test and treat" strategy for H. pylori followed by empirical acid suppression if negative or symptoms persist. 1
Clinical Reasoning
The patient's presentation—postprandial LUQ discomfort triggered by fatty meals with normal ultrasound, normal LFTs, and normal lipase—effectively excludes the major organic causes (gallbladder disease, pancreatitis, hepatobiliary pathology). Normal test results do not mean there is no cause; FD is caused by gut-brain axis dysfunction, visceral hypersensitivity, and altered gastric motility. 1
While LUQ pain is less typical than epigastric symptoms, the postprandial nature and fatty food trigger align with FD pathophysiology, particularly the postprandial distress syndrome (PDS) subtype characterized by meal-related symptoms. 2
Immediate Management Algorithm
Step 1: H. pylori Testing (First Priority)
- Order non-invasive H. pylori testing (stool antigen or urea breath test—NOT serology) 1
- If positive: Provide eradication therapy (strong recommendation, high-quality evidence)
- If negative or symptoms persist after eradication: Proceed to Step 2
Step 2: Empirical Acid Suppression
- Initiate PPI therapy at standard dose (e.g., omeprazole 20mg daily) 1
- Strong recommendation with high-quality evidence for efficacy in FD
- Use the lowest effective dose that controls symptoms
- Well-tolerated with minimal adverse effects
Step 3: Lifestyle Modifications
- Recommend regular aerobic exercise (strong recommendation) 1
- Advise avoiding specific fatty food triggers that worsen symptoms 1
- Important caveat: There is insufficient evidence for specialized diets (including low-FODMAP), and excessive dietary restriction risks malnutrition 1
When to Escalate Treatment
If symptoms persist after H. pylori treatment and PPI trial:
Second-Line Therapy
- Tricyclic antidepressants (TCAs) as neuromodulators: Start amitriptyline 10mg once daily, titrate slowly to 30-50mg daily 1
- Strong recommendation with moderate-quality evidence
- Explain this treats visceral hypersensitivity, NOT depression
- Counsel about side effects (dry mouth, drowsiness)
Alternative Second-Line Options
- Prokinetic agents (if available regionally—efficacy varies by drug class) 1
- Histamine-2 receptor antagonists (weak recommendation, low-quality evidence) 1
Red Flags Already Excluded
Your workup has appropriately ruled out:
- Biliary pathology: Normal ultrasound excludes cholelithiasis/cholecystitis
- Pancreatitis: Normal lipase (even mild elevations <3x ULN can cause diagnostic confusion, but normal lipase effectively excludes this) 3
- Hepatobiliary disease: Normal LFTs
Important Clinical Pitfalls
Don't order additional imaging or gastric emptying studies routinely—these are not recommended for typical FD 1
Don't use H. pylori serology—specificity is too low; use stool antigen or breath testing 1
Don't confirm H. pylori eradication unless the patient has increased gastric cancer risk 1
Age considerations: This patient doesn't require urgent endoscopy unless they are ≥55 years with weight loss, or >40 years with family history of gastro-esophageal cancer 1
When to Refer to Gastroenterology
Referral is appropriate if:
- Symptoms are severe or refractory to first-line and second-line treatments
- Diagnostic uncertainty persists
- Patient requests specialist opinion 1
Ideally, refer to a specialist FD clinic with access to dietetic support, neuromodulators, and gut-brain behavioral therapies (strong recommendation) 1
Prognosis and Patient Communication
Establish that FD is a real disorder of gut-brain interaction—not "all in their head." Explain that normal tests don't mean nothing is wrong; rather, the issue involves altered nerve sensitivity and communication between the gut and brain. 1 Stress, certain foods, and postinfectious changes can trigger symptoms. This explanation improves quality of life and reduces healthcare utilization. 1
The likelihood of serious pathology (cancer) remains extremely low even with further investigation. 1